

University of Groningen

Clinical Applications of [¹²³I]FP-CIT SPECT Imaging

Booij, Jan; Tijssen, Marina A.J.; Berendse, Henk W.

Published in:
PET and SPECT in Neurology

DOI:
[10.1007/978-3-030-53168-3_31](https://doi.org/10.1007/978-3-030-53168-3_31)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Booij, J., Tijssen, M. A. J., & Berendse, H. W. (2020). Clinical Applications of [¹²³I]FP-CIT SPECT Imaging. In *PET and SPECT in Neurology* (pp. 849-870). Springer International Publishing AG. https://doi.org/10.1007/978-3-030-53168-3_31

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Clinical Applications of [^{123}I]FP-CIT SPECT Imaging

31

Jan Booij, Marina A. J. Tijssen, and Henk W. Berendse

Contents

31.1	Introduction.....	850
31.2	Dopamine Transporter Imaging in Healthy Controls with [^{123}I]FP-CIT SPECT.....	851
31.3	[^{123}I]FP-CIT SPECT Imaging in Parkinson's Disease and Atypical Parkinsonian Syndromes.....	852
31.3.1	[^{123}I]FP-CIT SPECT Imaging in Parkinson's Disease.....	852
31.3.2	[^{123}I]FP-CIT SPECT Imaging in Multiple System Atrophy and Progressive Supranuclear Palsy.....	855
31.3.3	[^{123}I]FP-CIT SPECT Imaging in Corticobasal Degeneration.....	856
31.3.4	[^{123}I]FP-CIT SPECT Imaging in Vascular Parkinsonism and Traumatic Brain Injury.....	857
31.3.5	[^{123}I]FP-CIT SPECT Imaging in DLB.....	859
31.4	Methods to Analyse [^{123}I]FP-CIT SPECT Studies in Routine Clinical Practice.....	861
31.5	Extrastriatal [^{123}I]FP-CIT Binding.....	862
31.6	Concluding Remarks.....	863
	References.....	863

J. Booij (✉)

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers.
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
e-mail: j.booij@amsterdamumc.nl

M. A. J. Tijssen

Department of Neurology, University Medical Center Groningen, University of Groningen,
Groningen, The Netherlands
e-mail: m.a.j.de.koning-tijssen@umcg.nl

H. W. Berendse

Department of Neurology, Amsterdam University Medical Centers, VU University Medical
Center, Amsterdam, The Netherlands
e-mail: h.berendse@amsterdamumc.nl

© Springer Nature Switzerland AG 2021

R. A. J. O. Dierckx et al. (eds.), *PET and SPECT in Neurology*,
https://doi.org/10.1007/978-3-030-53168-3_31

849

Abstract

Dopamine transporter (DAT) imaging with [^{123}I]N- ω -fluoropropyl-2 β -carbomethoxy-3 β -(4-iodophenyl)nortropane ([^{123}I]FP-CIT) single-photon emission computed tomography (SPECT) is commonly used in routine clinical studies to exclude or detect a loss of striatal DATs in individual patients with a movement disorder or dementia. In this chapter, we describe the clinical applications of [^{123}I]FP-CIT SPECT imaging. To facilitate the interpretation of [^{123}I]FP-CIT SPECT images, we first describe the results of [^{123}I]FP-CIT SPECT studies in healthy controls. Thereafter, we describe the typical findings when applying this technique in movement disorders and dementia characterised by a loss of striatal DATs (e.g. Parkinson's disease and dementia with Lewy bodies). We will also describe the possibilities to analyse [^{123}I]FP-CIT SPECT scans in the setting of routine clinical practice. Finally, we briefly discuss the characterisation of extrastriatal [^{123}I]FP-CIT binding and its potential role in future studies.

31.1 Introduction

As described extensively in another chapter of this book series (Booij et al. 2020), the dopamine transporter (DAT) is mainly located in the membrane of presynaptic dopaminergic neurons (see Fig. 1 of Booij et al. 2020). Several radioligands for the DAT have been developed successfully for both positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging (for details see Booij et al. 2020). Yet, only a single radiotracer for the DAT has been licensed both by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA). This radiotracer is [^{123}I]N- ω -fluoropropyl-2 β -carbomethoxy-3 β -(4-iodophenyl)nortropane ([^{123}I]FP-CIT), which is marketed as DaTSCAN and DaTscan in Europe and the United States, respectively. [^{123}I]FP-CIT is a cocaine derivative that was first synthesised by the chemist John L. Neumeyer in the early 1990s (Neumeyer et al. 1994).

Currently, [^{123}I]FP-CIT SPECT is often used in routine clinical practice to exclude or detect the loss of nigrostriatal neurons in individual patients (Booij et al. 2001; Løkkegaard et al. 2002; Kupsch et al. 2012; Catafau et al. 2004).

In this chapter, we will discuss the potential clinical applications of [^{123}I]FP-CIT SPECT. We will first describe the results of studies performed in healthy control subjects and then discuss the role of [^{123}I]FP-CIT SPECT in differentiating between degenerative and non-degenerative movement disorders in clinical practice as well as its potential role in dementia. We will also discuss how [^{123}I]FP-CIT SPECT images can be analysed optimally as part of a routine clinical procedure. Finally, we will touch upon the potential role of extrastriatal [^{123}I]FP-CIT binding in future imaging studies.

31.2 Dopamine Transporter Imaging in Healthy Controls with [¹²³I]FP-CIT SPECT

In routine clinical studies, it is important to recognise abnormalities of striatal [¹²³I]FP-CIT binding on SPECT scans. Therefore, it is essential to be aware of the range of normal binding levels against which abnormal binding needs to be recognised. This will increase the diagnostic accuracy of [¹²³I]FP-CIT SPECT imaging in routine clinical practice. In this paragraph, we will discuss the results of [¹²³I]FP-CIT SPECT studies in healthy control subjects.

Autopsy studies in humans have shown a reduction in the number of pigmented neurons in the pars compacta of the substantia nigra with advancing age (McGeer et al. 1977; Fearnley and Lees 1991). In addition, autopsy studies showed that the concentration of striatal DATs declines with natural ageing (Allard and Marcusson 1989; De Keyser et al. 1990). In line with these pathological observations, [¹²³I]FP-CIT SPECT studies performed in healthy controls revealed decreases in striatal DAT binding with age, ranging from 3.3% up to 9.6% per decade (Ishikawa et al. 1996; Lavalaye et al. 2000; Tissingh et al. 1998; Eusebio et al. 2012; van de Giessen et al. 2013; Kaasinen et al. 2015; Yamamoto et al. 2017). The two largest [¹²³I]FP-CIT SPECT studies on this topic so far included 139 healthy controls (age range 20–83 years) and 256 healthy controls (age range 20–83 years), respectively, and reported an average decline of striatal DAT availability of 5.5–6.3% per decade (Varrone et al. 2013; Matsuda et al. 2018). Interestingly, one study included mainly Caucasians (Varrone et al. 2013), while the other included Asian subjects (Matsuda et al. 2018). Since the age-related decline in striatal DATs was comparable in both cohorts, this suggests that ageing effects on striatal DAT expression may be unrelated to race. Importantly, ageing had no effect on the caudate-to-putamen ratio of DAT binding (Fig. 31.1). This is in line with another large study in healthy controls




Fig. 31.1 [¹²³I]FP-CIT SPECT scan obtained (3 h after injection) in a 21-year-old healthy female control (*left side*) and in a 78-year-old healthy female control (*right side*). Striatal binding of [¹²³I]FP-CIT is symmetrical and clearly visible in both the caudate nucleus and putamen, in the young as well as the aged healthy control

using [^{123}I] β -CIT (a well-validated SPECT DAT tracer that is structurally closely related to [^{123}I]FP-CIT) and SPECT, which made clear that the rate of decline of DAT binding in the caudate nucleus and putamen with ageing was comparable (van Dyck et al. 2002). These findings suggest that it is important in routine clinical studies to take into account the effect of natural ageing on striatal DAT binding. A useful parameter, that is not influenced by natural ageing, is the caudate-to-putamen [^{123}I]FP-CIT binding ratio (Fig. 31.1).

Some [^{123}I]FP-CIT SPECT studies reported higher striatal binding ratios in women than in men (Lavalaye et al. 2000; Eusebio et al. 2012; Yamamoto et al. 2017; Matsuda et al. 2018), and this effect was more pronounced in younger than older controls (Lavalaye et al. 2000; Varrone et al. 2013; Matsuda et al. 2018), although this gender effect was not observed in all [^{123}I]FP-CIT studies (Pak et al. 2018). Also, an [^{123}I] β -CIT SPECT study performed in a large cohort of healthy controls (70 males and 52 females) did not find a significant effect of gender on striatal binding ratios (Best et al. 2005). Taken together, these data suggest that the diagnostic accuracy of [^{123}I]FP-CIT SPECT in routine clinical studies may be improved by taking gender effects into account, which may be particularly relevant in younger individuals.

[^{123}I] β -CIT SPECT studies in healthy controls demonstrated that the level of striatal DAT availability in the human brain may be associated with polymorphisms in the gene encoding for the DAT (van de Giessen et al. 2009; van Dyck et al. 2005; Jacobsen et al. 2000). However, a meta-analysis failed to establish a significant relationship between in vivo striatal DAT availability and polymorphisms in the gene encoding for the DAT in healthy controls (Costa et al. 2011). In a more recent meta-analysis, Faraone and co-workers concluded that the findings of SPECT studies on this topic were highly heterogeneous, and that the significant relationship between striatal DAT availability and polymorphisms in the gene encoding for the DAT may be limited to [^{123}I] β -CIT SPECT studies (Faraone et al. 2014). Also, to our knowledge no [^{123}I]FP-CIT SPECT study has been performed to look into this topic in a large group of healthy controls. Consequently, as it stands now, there is insufficient support to take gene effects into account in a setting in which [^{123}I]FP-CIT SPECT imaging is used for routine diagnostic purposes.


31.3 [^{123}I]FP-CIT SPECT Imaging in Parkinson's Disease and Atypical Parkinsonian Syndromes

31.3.1 [^{123}I]FP-CIT SPECT Imaging in Parkinson's Disease

An important neuropathological characteristic of Parkinson's disease (PD) is a severe loss of nigrostriatal dopamine neurons and consequently a decrease in striatal DATs (Kish et al. 1988; Kaufman and Madras 1991).

Several studies have established that [^{123}I]FP-CIT SPECT scanning can detect a loss of striatal DAT binding even in the early motor phase of PD (Eshuis et al. 2009; Isaias et al. 2007; Booij et al. 1997b; Tissingh et al. 1998; Pagano et al. 2018).


Fig. 31.2 [¹²³I]FP-CIT SPECT scan (3 h after injection) of a hemiparkinsonian patient. Note the asymmetry of binding, as well as the severe loss of binding bilaterally in the putamen



Typically, the reduction in striatal DAT binding is stronger in the putamen than in the caudate nucleus and has an asymmetrical pattern (Fig. 31.2). Most often, DAT binding is lowest in the contralateral putamen (i.e. the side contralateral to the most affected side of the body). However, in individual PD patients, the decrease in DAT binding can be rather symmetrical or even lower on the ipsilateral than on the contralateral side. It has been suggested that this last phenomenon may be particularly true for PD patients with tremor-dominant features (Isaias et al. 2007). Interestingly, in many patients with clinically unilateral PD, there is a bilateral loss of putamen DAT binding (Tissingh et al. 1998; Filippi et al. 2005), which is consistent with studies in hemi-PD patients using [¹²³I]β-CIT as a ligand (Marek et al. 1996) (Fig. 31.2). However, for routine clinical studies, it is important to be aware of the fact that in some patients with unilateral PD, the loss of DAT binding may be restricted to one side of the brain (Fig. 31.3).

In early-stage PD patients, using age-corrected data, an approximately 60–65% loss of DAT availability can be found in the contralateral putamen (Booij et al. 2001; Tissingh et al. 1998). Additionally, recent studies have suggested that [¹²³I]FP-CIT SPECT scanning is sensitive enough to detect a loss of striatal DAT binding in the premotor phase of PD (Iranzo et al. 2010, 2017; Stiasny-Kolster et al. 2005; Doppler et al. 2017), consistent with findings from earlier [¹²³I]β-CIT SPECT studies (Berendse et al. 2001; Ponsen et al. 2004, 2010). Finally, the loss of striatal [¹²³I]FP-CIT binding in PD correlates with the degree of rigidity and hypokinesia, but not with the severity of resting or postural tremor (Spiegel et al. 2007; Isaias et al. 2007).

Fig. 31.3 [^{123}I]FP-CIT SPECT scan (3 h after injection) of an early-stage PD patient. Note that in this hemi-parkinsonian patient (motor signs only on the right side of the body), the loss of striatal binding is restricted to the contralateral (*left*) striatum



Although, in most studies in PD, loss of striatal DAT binding does not correlate with tremor scores (Spiegel et al. 2007; Isaias et al. 2007), it has, however, been suggested that a widespread degeneration of the nigrostriatal dopaminergic pathway might still play a role in the aetiology of rest tremor in PD (Isaias et al. 2007). Interestingly, tremor-dominant PD patients can have significantly lower DAT binding in the striatum *ipsilateral* to the rest tremor as compared to akinetic-rigid PD patients (Isaias et al. 2007). Moreover, in some patients with a strictly unilateral resting tremor (without bradykinesia and rigidity), reduced DAT binding may be restricted to the *ipsilateral* (instead of the contralateral) side of the striatum (Aguirregomez et al. 2013; Lin and Chang 1997; Spiegel et al. 2007). These observations may be explained by degeneration/damage of ‘crossed’ dopaminergic fibres (Aguirregomez et al. 2013).

In some large clinical trials into which patients were enrolled based on a clinical diagnosis of PD, 11–15% of patients showed no degeneration of the nigrostriatal pathway. In the ELLDOPA study, 15% of the included PD patients who were scanned with [^{123}I]β-CIT SPECT had normal baseline scans (Parkinson study group 2002). Importantly, the follow-up scans remained normal in the patients who were rescanned 4 year later. These patients have since been referred to as scans without evidence of dopaminergic deficit (SWEDD; Fahn 2005). Also, a more recent [^{123}I]FP-CIT SPECT study of 16 SWEDD cases showed that after a mean follow-up of 5.4 years, repeat DAT imaging was normal in 14 of these cases (87.5%) (Batla et al. 2014). Recent studies suggest that many of these patients do not suffer from PD but from other conditions including dystonic tremor, parkinsonism associated with fragile X mental retardation 1 gene expansions or even non-neurological

diseases (Bajaj et al. 2010; Hall et al. 2010; Schneider et al. 2007; Sixel-Döring et al. 2011). These data emphasise the diagnostic power of DAT imaging.

In routine clinical studies, [¹²³I]FP-CIT SPECT is commonly used in inconclusive cases to differentiate PD from syndromes not characterised by nigrostriatal loss, for example, essential tremor or drug-induced parkinsonism (DIP) (Booij et al. 2001; Benamer et al. 2000; Marshall and Grosset 2003; Bajaj et al. 2013). In particular, the differentiation of PD from drug-induced parkinsonism (DIP) may present a diagnostic challenge to clinicians. Recent studies have shown that in this clinical situation, an abnormal [¹²³I]FP-CIT SPECT scan is indicative of an underlying neurodegenerative process as is common in PD (Bovi et al. 2010; Diaz-Corrales et al. 2010; Kägi et al. 2010; Tinazzi et al. 2009; Lim et al. 2013; Morley et al. 2016). DIP may persist beyond 6–9 months from the time of neuroleptic withdrawal, as was demonstrated in a recent report on two patients in whom DAT binding was normal (Lim et al. 2013). Importantly, for an accurate interpretation of [¹²³I]FP-CIT SPECT studies, it is not necessary to withdraw neuroleptics prior to the scanning procedure (Booij and Kemp 2008; Booij et al. 2010). Finally, a recent meta-analysis reported that [¹²³I]FP-CIT SPECT may be a useful imaging tool to differentiate PD from DIP (Brigo et al. 2014).

In summary, these findings suggest that [¹²³I]FP-CIT SPECT is a sensitive means to detect a loss of striatal DAT binding in PD. In routine clinical studies, [¹²³I]FP-CIT SPECT can be used to differentiate PD from other forms of parkinsonism that are not characterised by a loss of presynaptic dopaminergic neurons (e.g. essential tremor, psychogenic parkinsonism or DIP), in particular in clinically uncertain cases (Booij et al. 2001; Løkkegaard et al. 2002; Catafau et al. 2004; Cummings et al. 2011; Kägi et al. 2010; Marshall and Grosset 2003; Marshall et al. 2009; Kupsch et al. 2012; Bajaj et al. 2013).

31.3.2 [¹²³I]FP-CIT SPECT Imaging in Multiple System Atrophy and Progressive Supranuclear Palsy

Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders associated with parkinsonism that are also characterised neuropathologically by a loss of nigrostriatal cells and consequently a loss of DATs (Kish et al. 1985; Ruberg et al. 1985; Warren et al. 2007; González et al. 2000).

[¹²³I]FP-CIT SPECT has been used in several studies to demonstrate a loss of striatal DATs in MSA-P (MSA with predominantly parkinsonian signs) and PSP versus healthy controls (Antonini et al. 2003; El Fakhri et al. 2006; Plotkin et al. 2005; van Laere et al. 2006; Bae et al. 2016; Kim et al. 2016). Generally speaking, the results obtained using [¹²³I]FP-CIT as a ligand in MSA-P are in line with findings in studies using [¹²³I]β-CIT (Scherfler et al. 2005; Knudsen et al. 2004; Varrone et al. 2001; Seppi et al. 2006; Joling et al. 2017). In a prospective study, [¹²³I]FP-CIT SPECT scanning was sensitive enough to detect MSA-P in the premotor phase (Iranzo et al. 2010). A subject with rapid eye movement sleep behaviour disorder

but without parkinsonian signs had an abnormal [^{123}I]FP-CIT SPECT scan and developed MSA-P 2.5 years later.

Even in MSA-C (MSA-cerebellar subtype) patients without parkinsonian signs, a significant loss of striatal DAT binding compared to controls has been demonstrated using [^{123}I]FP-CIT SPECT (Muñoz et al. 2011). However, in comparison to patients with PD, MSA-P or PSP patients, the reported decrease in striatal DAT binding was relatively mild (an average loss of 20% of putamen DAT binding). Interestingly, the results of this SPECT study suggest that most but not all MSA-C patients without parkinsonism do have some degree of nigrostriatal dopaminergic denervation. The observation that a loss of DAT binding does not occur in all MSA-C cases (Bae et al. 2016; Joling et al. 2017; Vergnet et al. 2019) was confirmed by a post-mortem study in an autopsy-proven MSA-C case (Kolenc et al. 2012).

In most MSA-P and PSP patients, DAT binding in the putamen is lower than in the caudate nucleus. However, particularly in PSP, some studies suggested a more uniform loss of DATs in the putamen and caudate nucleus (Antonini et al. 2003), but this could not be reproduced by others (Seppi et al. 2006). Furthermore, some studies have shown that striatal DAT binding may differentiate MSA and/or PSP patients from PD patients at a group level (Goebel et al. 2011; Stoffers et al. 2005; Joling et al. 2017), although this is not a consistent finding in SPECT studies (Seppi et al. 2006). In any case, there is considerable overlap in striatal DAT binding values between groups, which suggests that in a routine clinical setting DAT imaging cannot be used to differentiate PD from MSA-P or PSP in individual cases (Stoffers et al. 2005). A recent post-mortem study of PD and MSA-P cases confirmed that the loss of striatal DAT was not significantly different between MSA and PD patients and also that the asymmetry of DAT binding was not significantly different between the two groups of patients (Perju-Dumbrava et al. 2012).

In summary, the results of the above-discussed studies suggest that [^{123}I]FP-CIT SPECT is a sensitive means to detect a loss of striatal DAT in MSA-P and PSP. However, it is important to emphasise that DAT imaging cannot be used to differentiate individual PD patients from MSA-P or PSP patients. Furthermore, striatal [^{123}I]FP-CIT binding can be normal in some MSA-C patients.

31.3.3 [^{123}I]FP-CIT SPECT Imaging in Corticobasal Degeneration

Corticobasal degeneration (CBD) is a rare syndrome, also characterised by nigrostriatal degeneration at autopsy (Oyanagi et al. 2001; Dickson et al. 2002). Indeed, an [^{123}I]FP-CT SPECT study that included the largest cohort of patients with a clinical diagnosis of probable CBD showed a loss of striatal DAT binding in 32 out of the 36 included patients (Cilia et al. 2011). In line with this observation, [^{123}I]β-CIT SPECT and other [^{123}I]FP-CIT SPECT studies in smaller groups of patients have also shown a loss of striatal DAT binding in CBD (Klaffke et al. 2006; Plotkin et al. 2005; Hammesfahr et al. 2016).




Fig. 31.4 [^{123}I] β -CIT SPECT scan of a healthy control (A) and a patient suffering from corticobasal degeneration (B), as well as an MR image of the same patient (C). The corticobasal degeneration has led to an asymmetrical degeneration of the nigrostriatal pathway (B) and a unilateral atrophy of the brain (C), both contralateral to the body side that showed clinical motor signs (Reprinted from ‘Bewegingsstoornissen’; editors ECh Wolters and T van Laar, Amsterdam, 2002, The Netherlands)

Intriguingly, Cilia et al. (2011) demonstrated that the loss of striatal [^{123}I]FP-CIT binding in their sample of CBD patients was characterised by a larger variability, more uniform striatal reduction and a greater asymmetry of binding than in PD patients. Indeed, DAT SPECT images in some CBD patients may be quite characteristic for CBD (Fig. 31.4), whereas in many other CBD cases the [^{123}I]FP-CIT SPECT images may look similar to the images obtained in PD patients. Even of more interest, in some sporadic autopsy-proven CBD cases an ante-mortem [^{123}I]FP-CIT SPECT scan showed no evidence of a reduction in striatal DAT binding (O’Sullivan et al. 2008; Walker et al. 2002). In the study by Cilia et al. (2011), there were no remarkable differences in clinical or neuropsychological characteristics between CBD subjects with or without abnormal striatal [^{123}I]FP-CIT binding. Apparently, extrapyramidal motor symptoms in CBD may not always be associated with nigrostriatal degeneration and could involve supranigral factors (Cilia et al. 2011).

For routine clinical studies, it is important to underline that in many, but not all CBD cases, an [^{123}I]FP-CIT SPECT scan is abnormal (Hammesfahr et al. 2016). In some cases, the pattern of striatal DAT loss may even be characteristic for CBD (Fig. 31.4).

31.3.4 [^{123}I]FP-CIT SPECT Imaging in Vascular Parkinsonism and Traumatic Brain Injury

Significant vascular lesions in the striatum or in the substantia nigra pars compacta can be associated with a loss of striatal [^{123}I]FP-CIT binding (Marshall and Grosset 2003; Zijlmans et al. 2002; Booij et al. 2018; Fig. 31.5), although initial [^{123}I] β -CIT




Fig. 31.5 MRI (susceptibility-weighted imaging) and [^{123}I]FP-CIT SPECT scan of the brain in a patient with vascular parkinsonism. The small lesion (hematoma) at the level of the substantia nigra (left panel) induced the abnormal SPECT scan. Please note that the [^{123}I]FP-CIT binding is normal in the right striatum, and abnormal in the posterior part of the left putamen. This pattern is atypical for Parkinson's disease since there is no gradual posterior-to-anterior loss of binding (reprinted from Booij et al. *Imago* 2018)

SPECT studies suggested that the vast majority of patients suffering from vascular parkinsonism had a normal [^{123}I]β-CIT SPECT scan (Gerschlagler et al. 2002).

In a hallmark paper by Zijlmans and co-workers (Zijlmans et al. 2007), even patients fulfilling clinical criteria for vascular parkinsonism and without vascular lesions in the striatum could have an abnormal [^{123}I]FP-CIT SPECT scan, with bilateral loss of DAT binding, particularly in the putamen. A [^{123}I]FP-CIT SPECT study in a large cohort of PD patients and patients with vascular parkinsonism confirmed these findings and showed that around 60–70% of SPECT scans were abnormal in vascular parkinsonism (Benítez-Rivero et al. 2013). Importantly, scores based on visual pattern recognition discriminated better between PD and vascular parkinsonism cases than semi-quantitative scores based on the positioning of regions of interest. Lastly, in another [^{123}I]FP-CIT SPECT study in PD patients and patients with vascular parkinsonism, a significant number of patients with vascular lesions in the basal ganglia had a normal SPECT scan, which indicates that vascular lesions in the basal ganglia do not always cause abnormal striatal DAT binding (Antonini et al. 2012). In the same study, a normal [^{123}I]FP-CIT SPECT scan was associated with a lack of benefit from dopaminomimetic treatment in over 90% of these subjects (Antonini et al. 2012). Finally, a recent meta-analysis concluded that [^{123}I]FP-CIT SPECT may be a useful imaging tool to differentiate PD from vascular parkinsonism (Brigo et al. 2014).

All in all, a substantial number of patients with vascular parkinsonism have an abnormal [^{123}I]FP-CIT SPECT. Frequently, it is possible to differentiate vascular parkinsonism from PD using [^{123}I]FP-CIT SPECT. To do so, it may be of utmost

importance to perform a careful visual inspection of the SPECT images (including structural images), and to recognise patterns of striatal DAT loss which are atypical for PD, but could support the diagnosis of vascular parkinsonism.

A recent study examined the effects of traumatic brain injury (TBI) on DAT binding (Jenkins et al. 2018). Forty-two moderate-severe TBI patients with cognitive impairments but without motor parkinsonism were examined. Around 20% of these patients had evidence of reduced DAT binding in the striatum as measured with [¹²³I]FP-CIT SPECT. Importantly, the caudate nucleus was affected more consistently than other striatal regions. Also, 11 patients had small, but visible, lesions in the striatum demonstrated by magnetic resonance imaging. Importantly, patients with lesions in these structures did not have different striatal DAT binding ratios compared to patients without lesions. These findings suggest that in the majority of patients with moderate/severe TBI, but without parkinsonism, the [¹²³I]FP-CIT SPECT scan is normal; in patients in whom such scans are rated as abnormal, the pattern of DAT loss may differ from what is typical for PD; and small lesions in the striatum may not influence significantly DAT loss as assessed by [¹²³I]FP-CIT SPECT.


In an older study, a severe reduction in striatal DAT binding, as measured by [¹²³I]β-CIT SPECT, was observed in a group of ten patients who were in a vegetative state or had persistent parkinsonism (Donnemiller et al. 2000).

31.3.5 [¹²³I]FP-CIT SPECT Imaging in DLB

Like other diseases characterised by Lewy body pathology (i.e. PD), also dementia with Lewy bodies (DLB) is associated with a loss of dopamine neurons and striatal DATs (Perry et al. 1998). By contrast, the loss of striatal DATs appears to be only subtle in patients suffering from Alzheimer's disease (Perry et al. 1998). In line with these autopsy findings, hallmark studies by Walker and colleagues demonstrated that ante-mortem DAT imaging with [¹²³I]FP-CIT SPECT substantially enhanced the accuracy of a diagnosis of DLB by comparison with clinical criteria alone (Walker et al. 2002, 2007). Many subsequent [¹²³I]FP-CIT SPECT studies confirmed the loss of striatal DATs in DLB (Auning et al. 2011; McKeith et al. 2007; Morgan et al. 2012; Roselli et al. 2009; van Laere et al. 2006; O'Brien et al. 2004; Siepel et al. 2013, 2016; Thomas et al. 2017; Jung et al. 2018). [¹²³I]FP-CIT SPECT may even detect a loss of striatal DAT binding in the pre-clinical phase of DLB (Iranzo et al. 2010; Thomas et al. 2019). Importantly, the results of [¹²³I]FP-CIT SPECT imaging may predict which patients with a clinical diagnosis of possible DLB will convert to probable DLB or to Alzheimer's disease (O'Brien et al. 2009). Finally, a meta-analysis indicated that the diagnostic accuracy of [¹²³I]FP-CIT SPECT in the diagnosis of DLB is high (Papathanasiou et al. 2012).

In most DLB patients, loss of striatal DAT binding is stronger in the putamen than in the caudate nucleus. Also, the loss of striatal DAT binding can be asymmetrical. However, in line with autopsy findings (Perry et al. 1998), the loss of striatal [¹²³I]FP-CIT binding can also be symmetrical with a relatively strong involvement

Fig. 31.6 [^{123}I]FP-CIT SPECT scan obtained (3 h after injection) in a DLB patient. Note that due to the strong reduction in specific binding of [^{123}I]FP-CIT in the striatum, the contrast between specific and non-specific binding is low. Also, the loss of binding is relatively symmetrical and involves both the caudate nucleus and putamen



of the caudate nucleus as compared to PD cases (Walker et al. 2004; Joling et al. 2018) (Fig. 31.6).

Although [^{123}I]FP-CIT SPECT appears to be very sensitive in differentiating between DLB and Alzheimer's disease, the role in the differential diagnosis between PD with dementia (PDD), frontotemporal dementia and DLB is probably limited, since a recent study showed that a third of frontotemporal dementia cases had an abnormal [^{123}I]FP-CIT SPECT scan (Morgan et al. 2012). Similarly, although at a group level loss of striatal DATs may be greater in PDD than DLB, the abnormalities on individual [^{123}I]FP-CIT SPECT scans (i.e. lower DAT binding in the putamen than caudate nucleus) in PDD may be similar to the abnormalities observed in DLB (O'Brien et al. 2004; Colloby et al. 2012).

Importantly, an autopsy study in DLB, PDD and Alzheimer's cases showed that ante-mortem DAT imaging was associated with post-mortem nigral dopaminergic neuronal density (but not α -synuclein, tau or amyloid burden) in demented patients (Colloby et al. 2012). This observation may cast doubt on the potential of DAT imaging to differentiate DLB patients without parkinsonism from Alzheimer's disease cases. Nevertheless, most DLB patients without parkinsonism have abnormal DAT SPECT scans (O'Brien et al. 2004; McKeith et al. 2007). On the other hand, Alzheimer's disease patients with parkinsonism may have normal scans (McKeith et al. 2007; Ceravolo et al. 2004).

The results of recent studies suggest that in a subgroup of probable DLB patients the [^{123}I]FP-CIT SPECT scan may be rated as normal initially, but becomes abnormal over time (Colloby et al. 2012; van der Zande et al. 2016; Thomas et al. 2017). This subgroup may consist of approximately 10% of DLB cases (van der Zande et al. 2016; Thomas et al. 2017), and the concept is that in these patients the Lewy bodies are expressed predominantly in the cortex, with initially only minimal involvement of the brainstem.

To summarise, there is evidence that [¹²³I]FP-CIT SPECT is helpful in differentiating DLB from Alzheimer's disease, but its role in differentiating DLB from frontotemporal dementia may be limited.

31.4 Methods to Analyse [¹²³I]FP-CIT SPECT Studies in Routine Clinical Practice

In routine clinical practice, many departments of nuclear medicine evaluate [¹²³I]FP-CIT SPECT scans by visual inspection only. Major reasons are a lack of age-matched control data and the fact that it is a simple way to analyse images. Although a visual qualitative analysis may seem inaccurate, this approach can in fact be very effective in excluding or confirming a loss of striatal DATs (Benamer et al. 2000; O'Brien et al. 2004; McKeith et al. 2007; Booij et al. 2017). An important advantage of visual analysis over a quantitative approach is that an abnormal pattern can be recognised rapidly. A recent study showed that a visual analysis approach was even more accurate in differentiating vascular parkinsonism from PD than a semi-quantitative approach (Benítez-Rivero et al. 2013). In addition, another large study on the diagnostic performance of [¹²³I]FP-CIT SPECT in patients with movement disorders or dementia showed that the results of combined reading (visual reading plus quantitative [¹²³I]FP-CIT SPECT data available to the reader) were not inferior to the results of the visual reading analysis, but the combined reading offered an increase in reader confidence (Booij et al. 2017). Moreover, the visual interpretation of [¹²³I]FP-CIT SPECT images can be further improved by visual rating of parametric distribution volume ratio images (Meyer et al. 2011). However, a visual analysis of [¹²³I]FP-CIT SPECT images may be less accurate in patients in which the degeneration is quite symmetrical and the involvement of the caudate nucleus and putamen more uniform. This type of pattern has been described in some DLB, PSP and MSA-C patients.

Even though visual assessment of [¹²³I]FP-CIT SPECT images remains an integral part of the study report, it is nowadays frequently supplemented by a quantification method (Tatsch and Poepperl 2012; Badiavas et al. 2011). Quantification does not only offer a more objective adjunct to an individual subjective judgement but also has the potential to detect subtle changes that can elude the human eye (Tatsch and Poepperl 2012) and may increase the reader confidence (Booij et al. 2017) and consistency between reporters (Taylor et al. 2018). In routine clinical DAT SPECT studies, semi-quantitative techniques using ROIs are commonly used due to their simplicity. Striatal ROIs were initially defined by manually drawing an irregular contour around the caudate nucleus and putamen and around a region devoid of DATs (occipital cortex or cerebellum). However, this method is strongly influenced by the intensity of striatal DAT binding. In other words, if there is decreased striatal [¹²³I]FP-CIT binding (e.g. in a PD case), the reader tends to draw smaller ROIs over striatal regions than in cases with more intense striatal [¹²³I]FP-CIT binding. Therefore, fixed (or predefined) ROIs are now used more frequently. These ROIs are derived from anatomical atlases or MR images and have led to a better

standardisation. However, this technique is still investigator dependent and does not take into account interindividual differences in striatal volumes. From this perspective, it is of interest that several (semi)automated quantification tools have been developed and several methods have been proposed to quantify DAT studies by (semi)automated positioning of ROIs or volumes of interest (VOIs) (Badiavas et al. 2011; Habraken et al. 1999). Examples are BasGan (Calvini et al. 2007), BRASS (Radau et al. 2000) and DaTQUANT (Brogley 2019) (for a comprehensive review, see Tatsch and Poepperl 2012). Voxel-based analysis, for example, using statistical parametric mapping (SPM), has also been used to analyse [123 I]FP-CIT SPECT studies (Kas et al. 2007; van de Giessen et al. 2013). Automated voxel-based image analyses may increase the diagnostic accuracy of DAT imaging in differentiating between PD and other parkinsonian syndromes (Goebel et al. 2011). Finally, in recent years, machine learning paradigms have been developed and evaluated successfully to classify [123 I]FP-CIT SPECT studies (Taylor and Fenner 2017; Taylor et al. 2018; Iwabuchi et al. 2019). However, future studies are needed to evaluate the feasibility of voxel-based techniques as well as machine learning paradigms in routine clinical practice.

As mentioned before, for an optimal interpretation of [123 I]FP-CIT SPECT images, ageing effects should be taken into account, and gender effects may be relevant in younger subjects. However, it may be difficult for departments of nuclear medicine to acquire [123 I]FP-CIT SPECT data in healthy controls and to build their own control database. The Neuroimaging Committee of the EANM understood this problem and decided to initiate a programme to overcome it by setting up an investigator-initiated multicentre trial using EARL (EANM Research Ltd) as a platform (Tatsch 2012). This initiative resulted in a highly standardised European database which is available to allow correction of quantitative DAT binding for age and gender, mostly independent of the equipment used and the centre performing the scan (Dickson et al. 2012; Tatsch 2012; Varrone et al. 2013).

For an optimal interpretation of [123 I]FP-CIT SPECT images, it is important to take into account the potential effects of the medication used on [123 I]FP-CIT binding to the DAT (for a review see Booij and Kemp 2008). Luckily, most dopaminergic drugs that are commonly used by patients suffering from parkinsonian or dementia syndromes (e.g. levodopa, dopamine agonists or acetylcholinesterase inhibitors) will not significantly influence [123 I]FP-CIT binding to the DAT and therefore do not have to be discontinued prior to routine [123 I]FP-CIT SPECT studies (Booij and Kemp 2008). On the other hand, selective serotonin reuptake inhibitors may increase striatal [123 I]FP-CIT binding ratios.

31.5 Extrastriatal [123 I]FP-CIT Binding

In vitro experiments have shown that [123 I]FP-CIT has a high affinity for the DAT (low nanomolar range), a moderate affinity for the serotonin transporter (SERT) and a negligible affinity for the norepinephrine transporter (Abi-Dargham et al. 1996;

Scheffel et al. 1997). It is well accepted that striatal [¹²³I]FP-CIT binding predominantly reflects binding to the DAT (Booij et al. 1997a; Andringa et al. 2005).

In recent years, extrastriatal [¹²³I]FP-CIT binding has gained attention (Booij et al. 2007; Eusebio et al. 2012; Hesse et al. 2009; Koopman et al. 2012; Roselli et al. 2010; Kaasinen et al. 2015; Joling et al. 2017, 2018; Joutsa et al. 2015). For example, [¹²³I]FP-CIT binding in the SERT-rich midbrain and diencephalon can be blocked with a selective serotonin reuptake inhibitor (SSRI) in healthy volunteers (Booij et al. 2007). In addition to the severe loss of striatal [¹²³I]FP-CIT binding, there is significantly lower midbrain [¹²³I]FP-CIT binding in DLB and PSP compared to PD patients (Roselli et al. 2010), and lower hypothalamic binding in PSP and MSA-p than in PD (Joling et al. 2017). Future studies will have to determine whether analysis of extrastriatal [¹²³I]FP-CIT binding is helpful in routine clinical studies.

31.6 Concluding Remarks

[¹²³I]FP-CIT SPECT is a very sensitive means to detect a loss of striatal DAT binding. This tool is particularly helpful in uncertain clinical cases with slight parkinsonian features, as well as in the differential diagnosis between syndromes characterised by nigrostriatal neuronal loss (e.g. PD or DLB) and syndromes in which the nigrostriatal system is spared (e.g. essential tremor or Alzheimer's disease).

References

- Abi-Dargham A, Gandelman MS, DeErasquin GA et al (1996) SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β -CIT. *J Nucl Med* 37:1129–1133
- Aguirregomozcorta M, Stamelou M, Antonini A et al (2013) Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. *J Neurol* 260:1132–1135
- Allard P, Marcusson JO (1989) Age-correlated loss of dopamine uptake sites with [3H]GBR-12935 in human putamen. *Neurobiol Aging* 10:661–664
- Andringa G, Drukarch B, Bol JG et al (2005) Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. *NeuroImage* 26:1150–1158
- Antonini A, Benti R, De Notaris R et al (2003) 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. *Neurol Sci* 24:149–150
- Antonini A, Vitale C, Barone P et al (2012) The relationship between cerebral vascular disease and parkinsonism: the VADO study. *Parkinsonism Relat Disord* 18:775–780
- Auning E, Rongve A, Fladby T et al (2011) Early and presenting symptoms of dementia with Lewy bodies. *Dement Geriatr Cogn Disord* 32:202–208
- Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N (2011) SPECT imaging evaluation in movement disorders: far beyond visual assessment. *Eur J Nucl Med Mol Imaging* 38:764–773
- Bae YJ, Kim JM, Kim E et al (2016) Loss of nigral hyperintensity on 3 Tesla MRI of parkinsonism: comparison with 123I-FP-CIT SPECT. *Mov Disord* 31:684–692

- Bajaj NP, Gontu V, Birchall J, Patterson J, Grosset DG, Lees AJ (2010) Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. *J Neurol Neurosurg Psychiatry* 81:1223–1228
- Bajaj N, Hauser RA, Grachev ID (2013) Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. *J Neurol Neurosurg Psychiatry* 84:1288–1295
- Batla A, Erro R, Stamelou M, Schneider SA, Schwingenschuh P, Ganos C, Bhatia KP (2014) Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. *Mov Disord* 29:1820–1825
- Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. *Mov Disord* 15:503–510
- Benítez-Rivero S, Marín-Oyaga VA et al (2013) Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. *J Neurol Neurosurg Psychiatry* 84:122–129
- Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, Wolters EC (2001) Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. *Ann Neurol* 50:34–41
- Best SE, Sarrel PM, Malison RT et al (2005) Striatal dopamine transporter availability with [123I]β-CIT SPECT is unrelated to gender or menstrual cycle. *Psychopharmacology* 183:181–189
- Booij J, Kemp P (2008) Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs. *Eur J Nucl Med Mol Imaging* 35:424–438
- Booij J, Andringa G, Rijks LJ et al (1997a) [¹²³I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. *Synapse* 27:183–190
- Booij J, Tissingh G, Boer GJ et al (1997b) [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. *J Neurol Neurosurg Psychiatry* 62:133–140
- Booij J, Speelman JD, Horstink MW, Wolters EC (2001) The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. *Eur J Nucl Med* 28:266–272
- Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL (2007) Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. *J Nucl Med* 48:359–366
- Booij J, van Amelsvoort T, Boot E (2010) Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome: potential role for dopamine transporter imaging. *Am J Med Genet A* 152A:2937–2938
- Booij J, Dubroff J, Pryma D, Yu J, Agarwal R, Lakhani P, Kuo PH (2017) Diagnostic performance of the visual reading of ¹²³I-ioflupane SPECT images with or without quantification in patients with movement disorders or dementia. *J Nucl Med* 58:1821–1826
- Booij J, Reneman L, Adriaanse S, de Bie R (2018) Dopaminetransporterscintigrafie bij patiënten met parkinsonisme. *Image* 2:37–42
- Booij J, van Wieringen JP, van de Giessen EM, Knol RJJ, Finnema SJ (2020) PET and SPECT imaging of the central dopamine system in humans. In: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Lammertsma AA (eds) PET and SPECT of neurobiological systems. Springer, New York, NY
- Bovi T, Antonini A, Ottaviani S et al (2010) The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. *J Neurol* 257:1882–1889
- Brigo F, Matinella A, Erro R, Tinazzi M (2014) [¹²³I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. *Eur J Neurol* 21:1369–1376
- Brogley JE (2019) DaTQUANT: the future of diagnosing Parkinson's disease. *J Nucl Med Technol* 47:21–26

- Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F (2007) The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. *Eur J Nucl Med Mol Imaging* 34:1240–1253
- Catafau AM, Tolosa E, DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group (2004) Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. *Mov Disord* 19:1175–1182
- Ceravolo R, Volterrani D, Gambaccini G et al (2004) Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. *J Neural Transm* 111:1065–1073
- Cilia R, Rossi C, Frosini D, Volterrani D et al (2011) Dopamine transporter SPECT imaging in corticobasal syndrome. *PLoS One* 6:e18301
- Colloby SJ, McParland S, O'Brien JT, Attems J (2012) Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. *Brain* 135:2798–2808
- Costa A, Riedel M, Müller U, Möller HJ, Ettinger U (2011) Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies. *Synapse* 65:998–1005
- Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P (2011) The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. *Brain* 134:3146–3166
- De Keyser JD, Ebinger G, Vauquelin G (1990) Age-related changes in the human nigrostriatal dopaminergic system. *Ann Neurol* 27:157–161
- Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P (2010) Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. *Eur J Nucl Med Mol Imaging* 37:556–564
- Dickson DW, Bergeron C, Chin SS et al (2002) Neuropathologic criteria for corticobasal degeneration. *J Neuropathol Exp Neurol* 61:935–946
- Dickson JC, Tossici-Bolt L, Sera T et al (2012) Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. *Eur J Nucl Med Mol Imaging* 39:188–197
- Donnemiller E, Brenneis C, Wissel J, Scherfler C, Poewe W, Riccabona G, Wenning GK (2000) Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. *Eur J Nucl Med* 27:1410–1414
- Doppler K, Jentschke HM, Schulmeyer L et al (2017) Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. *Acta Neuropathol* 133:535–545
- El Fakhri G, Habert MO, Maksud P, Kas A, Malek Z, Kijewski MF, Lacomblez L (2006) Quantitative simultaneous 99mTc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. *Eur J Nucl Med Mol Imaging* 33:87–92
- Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL (2009) Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. *Eur J Nucl Med Mol Imaging* 36:454–462
- Eusebio A, Azulay JP, Ceccaldi M, Girard N, Mundler O, Guedj E (2012) Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. *Eur J Nucl Med Mol Imaging* 39:1778–1783
- Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson's disease? *J Neurol* 252(Suppl 4):IV37–IV42
- Faraone SV, Spencer TJ, Madras BK, Zhang-James Y, Biederman J (2014) Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis. *Mol Psychiatry* 19:880–889
- Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain* 114:2283–2301
- Filippi L, Manni C, Pierantozzi M et al (2005) 123I-FP-CIT semi-quantitative SPECT detects pre-clinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. *Nucl Med Commun* 26:421–426

- Gerschlager W, Bencsits G, Pirker W et al (2002) [¹²³I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. *Mov Disord* 17:518–523
- Goebel G, Seppi K, Donnemiller E et al (2011) A novel computer-assisted image analysis of [¹²³I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. *Eur J Nucl Med Mol Imaging* 38:702–710
- González AM, Berciano J, Figols J, Pazos A, Pascual J (2000) Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration. *Brain Res* 852:228–232
- Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA (1999) Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. *J Nucl Med* 40:1091–1097
- Hall DA, Jennings D, Seibyl J, Tassone F, Marek K (2010) FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients. *Parkinsonism Relat Disord* 16:608–611
- Hammesfahr S, Antke C, Mamlins E et al (2016) FP-CIT- and IBZM-SPECT in corticobasal syndrome: results from a clinical follow-up study. *Neurodegener Dis* 16:342–347
- Hesse S, Meyer PM, Strecker K et al (2009) Monoamine transporter availability in Parkinson's disease patients with or without depression. *Eur J Nucl Med Mol Imaging* 36:428–435
- Iranzo A, Lomeña F, Stockner H et al (2010) Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. *Lancet Neurol* 9:1070–1077
- Iranzo A, Santamaría J, Valdeoriola F et al (2017) Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. *Ann Neurol* 82:419–428
- Isaias IU, Benti R, Cilia R et al (2007) [¹²³I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. *Neuroreport* 18:1499–1502
- Ishikawa T, Dhawan V, Kazumata K et al (1996) Comparative nigrostriatal dopaminergic imaging with iodine-123-bCIT-FP/SPECT and fluorine-18-FDOPA/PET. *J Nucl Med* 37:1760–1765
- Iwabuchi Y, Nakahara T, Kameyama M et al (2019) Impact of a combination of quantitative indices representing uptake intensity, shape, and asymmetry in DAT SPECT using machine learning: comparison of different volume of interest settings. *EJNMMI Res* 9:7
- Jacobsen LK, Staley JK, Zoghbi SS et al (2000) Prediction of dopamine transporter binding availability by genotype: a preliminary report. *Am J Psychiatry* 157:1700–1703
- Jenkins PO, De Simoni S, Bourke NJ (2018) Dopaminergic abnormalities following traumatic brain injury. *Brain* 141:797–810
- Joling M, Vriend C, van den Heuvel OA et al (2017) Analysis of extrastriatal 123I-FP-CIT binding contributes to the differential diagnosis of parkinsonian diseases. *J Nucl Med* 58:1117–1123
- Joling M, Vriend C, van der Zande JJ et al (2018) Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies. *Neuroimage Clin* 19:130–136
- Joutsa J, Johansson J, Seppänen M, Nojonen T, Kaasinen V (2015) Dorsal-to-ventral shift in mid-brain dopaminergic projections and increased thalamic/raphe serotonergic function in early Parkinson disease. *J Nucl Med* 56:1036–1041
- Jung Y, Jordan LG 3rd, Lowe VJ et al (2018) Clinicopathological and ¹²³I-FP-CIT SPECT correlations in patients with dementia. *Ann Clin Transl Neurol* 5:376–381
- Kaasinen V, Joutsa J, Nojonen T, Johansson J, Seppänen M (2015) Effects of aging and gender on striatal and extrastriatal [¹²³I]FP-CIT binding in Parkinson's disease. *Neurobiol Aging* 36:1757–1763
- Kägi G, Bhatia KP, Tolosa E (2010) The role of DAT-SPECT in movement disorders. *J Neurol Neurosurg Psychiatry* 81:5–12
- Kas A, Payoux P, Habert MO et al (2007) Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. *J Nucl Med* 48:1459–1467
- Kaufman MJ, Madras BK (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. *Synapse* 9:43–49

- Kim JM, Jeong HJ, Bae YJ et al (2016) Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. *Parkinsonism Relat Disord* 26:47–54
- Kish SJ, Chang LJ, Mirchandani L (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. *Ann Neurol* 18:530–536
- Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. *N Engl J Med* 318:876–880
- Klaffke S, Kuhn AA, Plotkin M, Amthauer H, Harnack D, Felix R, Kupsch A (2006) Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. *Mov Disord* 21:1724–1727
- Knudsen GM, Karlsborg M, Thomsen G et al (2004) Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. *Eur J Nucl Med Mol Imaging* 31:1631–1638
- Kolenc M, Popović M, Grmek M, Pirtošek Z, Trošt M (2012) A case of multiple system atrophy with normal dopamine transporter imaging. *J Neurol* 259:2719–2731
- Koopman KE, la Fleur SE, Fliers E, Serlie MJ, Booij J (2012) Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. *J Nucl Med* 53:1087–1090
- Kupsch AR, Bajaj N, Weiland F et al (2012) Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. *J Neurol Neurosurg Psychiatry* 83:620–628
- Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA (2000) Effect of age and gender on dopamine transporter imaging with [¹²³I]FP-CIT SPET in healthy volunteers. *Eur J Nucl Med* 27:867–869
- Lim TT, Ahmed A, Itin I, Gostkowski M, Rudolph J, Cooper S, Fernandez HH (2013) Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease? *Int J Neurosci* 123:170–174
- Lin JJ, Chang DC (1997) Tremor caused by ipsilateral chronic subdural hematoma. Case illustration. *J Neurosurg* 87:474
- Løkkegaard A, Werdelin LM, Friberg L (2002) Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. *Eur J Nucl Med Mol Imaging* 29:1623–1629
- Marek KL, Seibyl JP, Zoghbi SS et al (1996) [¹²³I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. *Neurology* 46:231–237
- Marshall V, Grosset D (2003) Role of dopamine transporter imaging in routine clinical practice. *Mov Disord* 18:1415–1423
- Marshall VL, Reiningner CB, Marquardt M et al (2009) Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [¹²³I]FP-CIT SPECT. *Mov Disord* 24:500–508
- Matsuda H, Murata M, Mukai Y et al (2018) Japanese multicenter database of healthy controls for [¹²³I]FP-CIT SPECT. *Eur J Nucl Med Mol Imaging* 45:1405–1416
- McGeer PL, McGeer EG, Suzuki J (1977) Aging and extrapyramidal function. *Arch Neurol* 34:33–35
- McKeith I, O'Brien J, Walker Z et al (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. *Lancet Neurol* 6:305–313
- Meyer PT, Winz OH, Dafotakis M, Werner CJ, Krohn T, Schäfer WM (2011) Improved visual [¹²³I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images. *Q J Nucl Med Mol Imaging* 55:301–309
- Morgan S, Kemp P, Booij J et al (2012) Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. *J Neurol Neurosurg Psychiatry* 83:1063–1070

- Morley JF, Cheng G, Dubroff JG, Wood S, Wilkinson JR, Duda JE (2016) Olfactory impairment predicts underlying dopaminergic deficit in presumed drug-induced parkinsonism. *Mov Disord Clin Pract* 28:603–606
- Muñoz E, Iranzo A, Rauek S et al (2011) Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C). *J Neurol* 258:2248–2253
- Neumeyer JL, Wang S, Gao Y et al (1994) N- ω -fluoroalkyl analogs of (1R)-2 β -carbomethoxy-3 β -(4-iodophenyl)-tropane (β -CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. *J Med Chem* 37:1558–1561
- O'Brien JT, Colloby S, Fenwick J et al (2004) Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. *Arch Neurol* 61:919–925
- O'Brien JT, McKeith IG, Walker Z et al (2009) Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. *Br J Psychiatry* 194:34–39
- O'Sullivan SS, Burn DJ, Holton JL, Lees AJ (2008) Normal dopamine transporter single photon-emission CT scan in corticobasal degeneration. *Mov Disord* 23:2424–2426
- Oyanagi K, Tsuchiya K, Yamazaki M, Keda K (2001) Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features. *J Neuropathol Exp Neurol* 60:393–402
- Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M (2018) REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. *Neurology* 91:894–905
- Pak K, Nam HY, Shin S et al (2018) Effects of rs591323 on serotonin transporter availability in healthy male subjects. *Ann Nucl Med* 32:431–436
- Papathanasiou ND, Boutsidiadis A, Dickson J, Bomanji JB (2012) Diagnostic accuracy of ¹²³I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. *Parkinsonism Relat Disord* 18:225–229
- Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of Pramipexole vs levodopa Parkinson disease progression. *JAMA* 287:1653–1661
- Perju-Dumbrava LD, Kovacs GG, Pirker S, Jellinger K, Hoffmann M, Asenbaum S, Pirker W (2012) Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. *Mov Disord* 27:65–71
- Perry E, Court J, Goodchild R et al (1998) Clinical neurochemistry: developments in dementia research based on brain bank material. *J Neural Transm* 105:915–933
- Plotkin M, Amthauer H, Klaffke S et al (2005) Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. *J Neural Transm* 112:677–692
- Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson's disease. *Ann Neurol* 56:173–181
- Ponsen MM, Stoffers D, Wolters EC, Booij J, Berendse HW (2010) Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. *J Neurol Neurosurg Psychiatry* 81:396–399
- Radau PE, Linke R, Slomka PJ, Tatsch K (2000) Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. *J Nucl Med* 41:220–227
- Roselli F, Pisciotta NM, Pernecky R et al (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. *Mov Disord* 24:2097–2103
- Roselli F, Pisciotta NM, Pennelli M et al (2010) Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. *Mov Disord* 25:1853–1859
- Ruberg M, Javoy-Agid F, Hirsch E et al (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. *Ann Neurol* 18:523–529
- Scheffel U, Lever JR, Abraham P et al (1997) N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. *Synapse* 25:345–349
- Scherfler C, Seppi K, Donnemiller E et al (2005) Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. *Brain* 128:1605–1612

- Schneider SA, Edwards MJ, Mir P, Cordivari C, Hooker J, Dickson J, Quinn N, Bhatia KP (2007) Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). *Mov Disord* 22:2210–2215
- Seppi K, Scherfler C, Donnemiller E et al (2006) Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [¹²³I]beta-CIT SPECT analysis. *Arch Neurol* 63:1154–1160
- Siepel FJ, Rongve A, Buter TC, Beyer MK, Ballard CG, Booij J, Aarsland D (2013) (123I) FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. *BMJ Open* 3(4):pii: e002642
- Siepel FJ, Dalen I, Grüner R, Booij J, Brønnick KS, Buter TC, Aarsland D (2016) Loss of dopamine transporter binding and clinical symptoms in dementia with Lewy bodies. *Mov Disord* 31:118–125
- Sixel-Döring F, Liepe K, Mollenhauer B, Trautmann E, Trenkwalder C (2011) The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. *J Neurol* 258:2147–2154
- Spiegel J, Hellwig D, Samnick S et al (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. *J Neural Transm* 114:331–335
- Stiasny-Kolster K, Doerr Y, Möller JC et al (2005) Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. *Brain* 128:126–137
- Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW (2005) Early-stage [¹²³I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. *Eur J Nucl Med Mol Imaging* 32:689–695
- Tatsch K (2012) Standardisation and harmonisation boost the credibility of nuclear medicine procedures. *Eur J Nucl Med Mol Imaging* 39:186–187
- Tatsch K, Poepperl G (2012) Quantitative approaches to dopaminergic brain imaging. *Q J Nucl Med Mol Imaging* 56:27–38
- Taylor JC, Fenner JW (2017) Comparison of machine learning and semi-quantification algorithms for (123)FP-CIT classification: the beginning of the end for semi-quantification? *EJNMMI Phys* 4:29
- Taylor JC, Romanowski C, Lorenz E, Lo C, Bandmann O, Fenner J (2018) Computer-aided diagnosis for (123I)FP-CIT imaging: impact on clinical reporting. *EJNMMI Res* 8:36
- Thomas AJ, Attems J, Colloby SJ et al (2017) Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. *Neurology* 88:276–283
- Thomas AJ, Donaghy P, Roberts G et al (2019) Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. *Psychol Med* 49:396–402
- Tinazzi M, Antonini A, Bovi T et al (2009) Clinical and [¹²³I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. *J Neurol* 256:910–915
- Tissingh G, Booij J, Bergmans P et al (1998) Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. *J Nucl Med* 39:1143–1148
- van de Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J (2009) Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. *J Nucl Med* 50:45–52
- van de Giessen EV, Hesse S, Caan MW et al (2013) No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. *NeuroImage* 64:61–67
- van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW (2016) [¹²³I]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. *Eur J Nucl Med Mol Imaging* 43:1060–1066
- van Dyck CH, Seibyl JP, Malison RT et al (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. *Am J Geriatr Psychiatry* 10:36–43

- van Dyck CH, Malison RT, Jacobsen LK et al (2005) Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. *J Nucl Med* 46:745–751
- Van Laere K, Casteels C, De Ceuninck L et al (2006) Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. *J Nucl Med* 47:384–392
- Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP (2001) [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. *Mov Disord* 16:1023–1032
- Varrone A, Dickson JC, Tossici-Bolt L et al (2013) European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. *Eur J Nucl Med Mol Imaging* 40:213–227
- Vergnet S, Hives F, Foubert-Samier A (2019) Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. *Parkinsonism Relat Disord* 63:199–203
- Walker Z, Costa DC, Walker RW et al (2002) Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. *J Neurol Neurosurg Psychiatry* 73:134–140
- Walker Z, Costa DC, Walker RW et al (2004) Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. *Neurology* 62:1568–1572
- Walker Z, Jaros E, Walker RW et al (2007) Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. *J Neurol Neurosurg Psychiatry* 78:1176–1181
- Warren NM, Piggott MA, Grealley E, Lake M, Lees AJ, Burn DJ (2007) Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy. *Mov Disord* 22:1594–1600
- Yamamoto H, Arimura S, Nakanishi A et al (2017) Age-related effects and gender differences in Japanese healthy controls for [¹²³I] FP-CIT SPECT. *Ann Nucl Med* 31:407–412
- Zijlmans J, Booij J, Valk J, Lees A, Horstink M (2002) Posttraumatic tremor without parkinsonism in a patient with complete contralateral loss of the nigrostriatal pathway. *Mov Disord* 17:1086–1088
- Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacinovic S, Lees AJ, Costa D (2007) [123I]FP-CIT spect study in vascular parkinsonism and Parkinson's disease. *Mov Disord* 22:1278–1285